🇺🇸 UMEC/VI in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1
Most-reported reactions
- Chronic Obstructive Pulmonary Disease — 1 report (100%)
Other Respiratory / Pulmonology approved in United States
Frequently asked questions
Is UMEC/VI approved in United States?
UMEC/VI does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for UMEC/VI in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.